Minami M, Driscoll E M, Simpson P J, Hoff P T, Lucchesi B R
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Higashi-Nippon-Gakuen University, Hokkaido, Japan.
Pharmacology. 1995 Jan;50(1):24-33. doi: 10.1159/000139263.
This study was performed to assess the effect of BMY21190, an inhibitor of cAMP phosphodiesterase, on infarct size using a canine ischemic model that underwent a 90-min occlusion and a 6-hour reperfusion of the left coronary artery. The infarct zone/area at risk of the BMY21190 group was significantly smaller than that of the vehicle group (36.1 +/- 7.8%; 62.4 +/- 4.3%, respectively; p < 0.05). Myeloperoxidase activity, an indicator of neutrophil infiltration, was significantly correlated to infarct size (r = 0.6893, p < 0.02). Myeloperoxidase activity (0.14 +/- 0.07 U/100 mg tissues) measured in the area at risk from hearts of the BMY21190-treated group was significantly lower than that of the vehicle-treated tissue (0.40 +/- 0.08 U/100 mg tissue, p < 0.05). It is suggested that BMY21190 reduces infarct size through the inhibition of neutrophil infiltration in the canine model.
本研究旨在使用犬类缺血模型评估环磷酸腺苷磷酸二酯酶抑制剂BMY21190对梗死面积的影响，该模型经历了90分钟的左冠状动脉闭塞和6小时的再灌注。BMY21190组的梗死区/危险面积显著小于载体组（分别为36.1±7.8%和62.4±4.3%；p<0.05）。髓过氧化物酶活性作为中性粒细胞浸润的指标，与梗死面积显著相关（r = 0.6893，p < 0.02）。在接受BMY21190治疗的组中，心脏危险区域测得的髓过氧化物酶活性（0.14±0.07 U/100 mg组织）显著低于接受载体治疗的组织（0.40±0.08 U/100 mg组织，p < 0.05）。提示在犬类模型中，BMY21190通过抑制中性粒细胞浸润来减小梗死面积。
